MEDICAL CHEMICAL DEFENSE (ACD&P)
Abstract
This Project provides for the development of medical materiel and other medical equipment items necessary for the Technology Development phase of the acquisition life cycle for the advanced development of medical countermeasures (MCMs) for chemical warfare agents including diagnostic equipment, prophylactic, pre-treatment, and therapeutic drugs, and individual/casualty decontamination compounds. A family-of-systems approach for medical defense against chemical warfare agents is required to provide protection, to sustain performance in a chemical environment, and to provide for self-aid/buddy-aid and medical treatment of chemical casualties. Fielding of prophylactic, pre-treatment, and therapeutic drugs and medical devices requires Food and Drug Administration (FDA) approval. Given the family-of-systems approach for development of chemical MCMs for the treatment of nerve agent intoxication, multiple long-term studies are required to obtain FDA approval to deliver products that effectively integrate with current and projected therapeutic regimens. Efficacy testing of most candidate drugs against chemical warfare agents cannot be conducted in humans; therefore, animal surrogate models must be developed and employed. The program currently includes: Improved Nerve Agent Treatment System (INATS) an enhanced nerve agent treatment regimen consisting of an improved oxime to replace the current fielded oxime 2-pralidoxime chloride (2-PAM). The Improved Nerve Agent Treatment System (INATS) advanced development provides an enhanced capability treatment regimen offering greater protection over a broader spectrum of toxic nerve agent threats. Components of the development include (1) a new and improved oxime (replacing 2-pralidoxime chloride (2-PAM)) to provide protection across current and emerging threats, (2) expanded nerve agent indications for a fielded, single indication, pyridostigmine bromide (PB) product, and (3) insertion of a centrally-acting (CA) anticholinergic agent to the treatment regimen to increase survivability and decrease morbidity. The INATS treatment regimen both improves the performance of, and eventually replaces the Antidote Treatment Nerve Agent Auto-injector (ATNAA), while expanding warfighter pretreatment options.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2017
- Source ID
- MC4_0603884BP_4_0400_PB_2017
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (ACD&P)
- Child Accomplishment: 1) INATS
- Child Accomplishment: 2) INATS
- Child Accomplishment: 3) INATS
- Child Cost Item: 0f394f19948311ca0f9ff251ff1ddcda
- Child Cost Item: 6b6782a8f1b87108ae945304bf442c70
- Child Cost Item: e033aa6bda3e26da63c5c343fd75ff3e
- Child Cost Item: 1c02dd0607a4bce7ba473719aa15bbbd
- Child Cost Item: ff2a54a6fdbf313b23749384359238e0